Healthcare Industry News: peripheral stent
News Release - January 27, 2010
Invatec Completes its Maris Plus Self-Expanding Peripheral Stent System at LINC 2010
Tailored Stent for Superficial Femoral Artery Stenting now availableLEIPZIG, Germany--(HSMN NewsFeed)--Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
The Maris Plus stent features an exclusive cell design at the stent ends. This allows physicians to place several stents in series without stiffening the artery in the overlap region. The Maris Plus becomes the sixth stent platform now marketed by Invatec for the treatment of Peripheral Arterial Disease (PAD), greatly optimising visibility, flexibility and ease of use for the physician.
“It was our goal to offer dedicated stent geometries to respond to the different needs of the iliac and SFA arteries. With the Maris Plus, we have created a stent with an overlap region that allows two stents to act like one in the femoral artery,” said Stefan Widensohler and Andrea Venturelli, co-founders of Invatec. The distinct design provides excellent flexibility, fracture resistance, and tailored deployment. Additionally, larger and fully integrated tantalum markers greatly enhance visibility for the physician.
About Invatec
Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collaborates with physicians and centres of excellence to develop products that will improve life expectancy and quality of life for patients. Vertically integrated, Invatec also has the in-house ability to design, develop, manufacture and assemble its entire product offering from raw materials. As a result, the company has one of the largest therapeutic catheter product lines in the world, including 10 stent platforms, 7 angioplasty balloon platforms, 4 drug-eluting balloon platforms and accessory devices, now sold in over 70 countries.
Dedicated to "making ideas come alive," the company was founded in 1996 by Andrea Venturelli and Stefan Widensohler, and has grown to almost 1,000 employees. For more information, visit www.invatec.com.
Source: Invatec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
